Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsCigna Givlaari Prior Auth Update | OpenPayer
    Ask Trek AI about this page
    CurrentCignaPolicy IP0118

    Hepatology - Givlaari

    Customize your policy alerts

    Sign up for Cigna Policy IP0118 alerts

    Get alerted when Policy IP0118 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and benefit coverage for Givlaari (givosiran) for patients with acute hepatic porphyria, subject to the applicable benefit plan, laws, and individual clinical circumstances.

    Policy Summary
    PayerCigna
    PolicyHepatology - Givlaari
    Policy CodePolicy IP0118
    Change TypeMaterial policy revision
    Effective DateNov 15, 2026
    Last ReviewOct 29, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization with documentation that the patient meets all acute hepatic porphyria criteria and established dosing requirements.
    SourceLink
    POLICY UPDATE CHANGES

    The initial approval duration for acute hepatic porphyria was increased from 6 months to 1 year.

    The biochemical diagnostic criterion was revised to require elevated urinary porphobilinogen rather than elevated urinary or plasma porphobilinogen.

    The prerequisite acute attack criterion was revised to specify intravenous hemin administration at home.

    The medical geneticist was removed from the list of acceptable prescribing or consulting specialists.

    Reauthorization criteria were removed from the policy revision history.

    ≥18 yearsMinimum patient age
    1 year

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Initial approval duration
    1 attack / 6 monthsQualifying attack history
    2.5 mg/kg monthlyRecommended dose
    J0223Covered HCPCS code
    Not medically necessaryOther uses

    Coverage Criteria

    Initial therapy for acute hepatic porphyria

    Covered for 1 year when ALL of the following are met:

    Patient and diagnosis requirements

    • Age: Patient is at least 18 years of age.≥ 18 years
    • Confirmed diagnosis

      • Clinical features: The patient has demonstrated clinical features associated with acute hepatic porphyria.

        Documentation required. Examples include neurovisceral symptoms, blistering lesions, hepatic involvement, peripheral neuropathy, abdominal pain, constipation, muscle weakness, and pain in the arms and legs.

      • ONE of

        • Urinary ALA: Elevated urinary aminolevulinic acid (ALA) greater than the upper limit of normal.greater than the upper limit of normal

          Documentation required.

        • Urinary PBG: Elevated urinary porphobilinogen (PBG) greater than the upper limit of normal.greater than the upper limit of normal

          Documentation required.

    • Qualifying attack history: Before starting treatment with Givlaari, the patient had a history of one porphyria attack in the last 6 months requiring hospitalization, an urgent healthcare visit, or intravenous hemin administration at home.At least 1 qualifying attack in the prior 6 months
    • Specialist involvement: Givlaari is prescribed by or in consultation with a gastroenterologist, hepatologist, or physician who specializes in acute hepatic porphyria.
    • Dosing: Givlaari is administered at 2.5 mg/kg by subcutaneous injection no more frequently than once every 30 days.2.5 mg/kg; no more frequently than once every 30 days

    Givlaari is not medically necessary for any use other than the covered indication of acute hepatic porphyria.

    Givlaari for any other use is considered not medically necessary.

    Coding and Clinical Parameters

    Medically Necessary HCPCS CodesHCPCSCovered
    J0223Injection, givosiran, 0.5 mg
    Age
    Minimum covered age≥ 18 years
    Urinary aminolevulinic acid
    Required levelGreater than the upper limit of normal
    Urinary porphobilinogen
    Required levelGreater than the upper limit of normal
    Qualifying porphyria attack history
    Minimum history

    Provider Actions and Submission Requirements

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for benefit coverage of Givlaari. Approval depends on meeting the policy criteria and dosing requirements; extended approvals require the patient to continue meeting those requirements.

    Prior Authorization

    Specialist Prescribing or Consultation Required

    Givlaari must be prescribed by or in consultation with an eligible specialist because evaluation, diagnosis, monitoring, and management require specialized skills.

    • Eligible prescribers or consultants include a gastroenterologist, hepatologist, or physician who specializes in acute hepatic porphyria.
    Documentation Required

    Required Clinical Documentation

    Clinical Background

    Acute hepatic porphyrias are liver-based metabolic disorders caused by impaired heme production. They may produce acute neurovisceral symptoms, with or without cutaneous manifestations.

    Policy Definitions

    Acute hepatic porphyria (AHP)
    DefinitionA subgroup of porphyrias in which the enzyme deficiency occurs within the liver
    Included subtypesAcute intermittent porphyria, variegate porphyria, 5-aminolevulinic acid dehydratase deficiency porphyria, and hereditary coproporphyria
    Givlaari
    DefinitionAn aminolevulinate synthase 1-directed small interfering RNA
    MechanismCauses degradation of ALAS1 mRNA in hepatocytes through RNA interference, reducing circulating aminolevulinic acid and porphobilinogen
    RouteAdministered by subcutaneous injection
    Covered treatment context

    Initial Therapy

    Acute hepatic porphyria

    Approve for 1 year if the patient meets ALL of the following criteria:

    • Age: Patient is at least 18 years of age.≥ 18 years
    • Confirmed diagnosis

      • Clinical features: The patient has demonstrated clinical features associated with acute hepatic porphyria.

        Documentation required. Examples include neurovisceral symptoms, blistering lesions, hepatic involvement, peripheral neuropathy, abdominal pain, constipation, muscle weakness, and pain in the arms and legs.

      • ONE of

    Extended Approval

    Extended approval

    Extended approvals are allowed when the patient continues to meet the applicable criteria and dosing requirements.

    Continuation therapy: The patient continues to meet the applicable acute hepatic porphyria criteria and established Givlaari dosing requirements.

    Requests for doses outside the established dosing are considered on a case-by-case basis by a clinician. The policy does not provide separate reauthorization criteria.

    Dose and Quantity Limits

    Givlaari dose
    Covered dose2.5 mg/kg
    AdministrationSubcutaneous injection
    Dosing frequencyOnce monthly; no more frequently than once every 30 days

    Administration Site Requirements

    Billing Rule

    Administer Givlaari in the office

    Givlaari must be administered by a healthcare professional in the office setting.

    Policy Summary
    PayerCigna
    PolicyHepatology - Givlaari
    Policy CodePolicy IP0118
    Change TypeMaterial policy revision
    Effective DateNov 15, 2026
    Last ReviewOct 29, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization with documentation that the patient meets all acute hepatic porphyria criteria and established dosing requirements.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Clinical ParametersProvider Actions and Submission RequirementsClinical BackgroundPolicy DefinitionsInitial TherapyExtended ApprovalDose and Quantity LimitsAdministration Site Requirements
    At least 1 porphyria attack in the last 6 months
    Qualifying treatment or careThe attack required hospitalization, an urgent healthcare visit, or intravenous hemin administration at home
    Givlaari dosing interval
    Dose and route2.5 mg/kg subcutaneous injection
    Maximum frequencyNo more frequently than once every 30 days

    Submit documentation where the criteria identify it as required. Supporting records must include patient-specific identifying information and may include chart notes, laboratory tests, claims records, and other relevant information.

    • Documentation is required for clinical features associated with acute hepatic porphyria.
    • Documentation is required for qualifying urinary aminolevulinic acid or urinary porphobilinogen elevation.
    Documentation Required

    Document Clinical Features

    Document clinical features associated with acute hepatic porphyria to support the diagnosis.

    • Examples include neurovisceral symptoms, blistering lesions, hepatic involvement, peripheral neuropathy, abdominal pain, constipation, muscle weakness, and pain in the arms and legs.
    Documentation Required

    Biochemical Confirmation Required

    Provide laboratory documentation confirming acute hepatic porphyria through qualifying urinary biochemical findings.

    • Elevated urinary aminolevulinic acid (ALA) greater than the upper limit of normal; or
    • Elevated urinary porphobilinogen (PBG) greater than the upper limit of normal.
    Denial Risk

    Failure to Meet Indication Criteria

    Coverage may be denied when required indication criteria are not met. Givlaari is approved for patients who are at least 18 years old with confirmed acute hepatic porphyria, the required recent attack history, and an eligible specialist prescriber or consultant; use for any other indication is not medically necessary.

    • Patient must be ≥ 18 years of age.
    • Diagnosis must be confirmed by both documented clinical features and qualifying urinary ALA or PBG elevation.
    • Before treatment, the patient must have had an attack within the last 6 months requiring hospitalization, an urgent healthcare visit, or intravenous hemin administration at home.
    • Givlaari for any other use is considered not medically necessary.
    Denial Risk

    Nonstandard Dosing Requires Case-by-Case Review

    The established dosing is 2.5 mg/kg by subcutaneous injection no more frequently than once every 30 days. Requests outside this dosing frequency are reviewed case by case by a clinician, such as a Medical Director or Pharmacist.

    Billing Rule

    Unsupported Coding May Result in Denial

    Claims may be denied when they are submitted without covered diagnosis or procedure codes, or when codes are missing, invalid, deleted, or not effective on the date of service. Providers must use the most appropriate codes effective on the submission date.

    • Reimbursement is not allowed for services billed for conditions or diagnoses not covered under the policy.
    • Deleted or date-inapplicable codes may not be eligible for reimbursement.
    Treatment of acute hepatic porphyria in patients ≥ 18 years of age
    Urinary ALA: Elevated urinary aminolevulinic acid (ALA) greater than the upper limit of normal.greater than the upper limit of normal

    Documentation required.

  1. Urinary PBG: Elevated urinary porphobilinogen (PBG) greater than the upper limit of normal.greater than the upper limit of normal

    Documentation required.

  2. Qualifying attack history: Before starting treatment with Givlaari, the patient had a history of one porphyria attack in the last 6 months requiring hospitalization, an urgent healthcare visit, or intravenous hemin administration at home.At least 1 qualifying attack in the prior 6 months
  3. Specialist involvement: Givlaari is prescribed by or in consultation with a gastroenterologist, hepatologist, or physician who specializes in acute hepatic porphyria.
  4. Dosing: Givlaari is administered at 2.5 mg/kg by subcutaneous injection no more frequently than once every 30 days.2.5 mg/kg; no more frequently than once every 30 days